Dose-specific effectiveness of 7- and 13-valent pneumococcal conjugate vaccines against vaccine-serotype Streptococcus pneumoniae colonization in children.
Reduced-dose pneumococcal conjugate vaccine (PCV) schedules are under consideration in countries where children are recommended to receive three doses. Whereas PCV-derived protection against vaccine-serotype colonization is responsible for herd effects of vaccination, dose-specific PCV effectiveness against colonization endpoints is not known. We aimed to assess the performance of differing PCV schedules against vaccine-serotype colonization in children. From 2009-2016, we monitored pneumococcal carriage in southern Israel, where children should receive PCV at ages 2m, 4m, and 12m (2p+1b schedule). We analyzed nasopharyngeal swabs and vaccination histories from 5928 children ages 0-59m without symptoms of diseases potentially attributable to pneumococci. Matching individuals on age, sex, ethnicity, visit timing, and recent antibiotic receipt, we measured schedule-specific PCV7/13 effectiveness against vaccine-serotype colonization in a modified case-control framework. We sampled from the distribution of all possible case-control match assignments for statistical analyses. Two primary-series PCV13 doses conferred 53% (95%CI: 32-67%) protection against PCV13-serotype colonization at ages ≤12m; one primary-series dose was not protective. A 2p+1b PCV13 series conferred 40% (4-67%) and 62% (33-83%) protection against PCV13-serotype colonization at ages 13-24m and 25-59m, respectively. Estimates suggested greater PCV13-conferred protection against PCV7-targeted serotypes than the six PCV13-only serotypes. As compared to children receiving 2p+1b PCV13 dosing, those receiving 1p+1b and 2p+0b schedules experienced 2.05 (1.12-5.00)-fold and 3.33 (2.28-4.93)-fold greater odds, respectively, of vaccine-serotype pneumococcal colonization at ages 13-24m. Our results demonstrate real-world effectiveness of 2p+1b PCV dosing against vaccine-serotype colonization. Reduced-dose schedules may confer lower protection against vaccine-serotype carriage during and beyond the first year of life.